Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

Torsten Steinbrunn, Ryosuke Shirasaki, Olga Dashevsky, Huihui Tang, Shizuka Yamano, Rin Mizuno, Takeru Sugihara, Phaik Ju Teoh, Lisa B Leypoldt, Mariko Kaji, Jeffrey Sorrell, Brian J Glassner, Ricardo De Matos Simoes, James Christensen, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2023-182476

Published: 2023

Journal Articles

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142580

Published: 2020

Journal Articles

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Sara Gandolfi, MD, Huihui Tang, PhD, Sondra L. Downey-Kopyscinski, PhD, Megan Bariteau, B.Sc., Jeffrey Sorrell, BA, Brian Glassner, PhD, John Doench, PhD, Larry H. Boise, PhD, Jonathan D. Licht, MD, Aedin Culhane, PhD, William C. Hahn, MD PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-142651

Published: 2020

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors — Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications

Ryosuke Shirasaki, MD, Ricardo De Matos Simoes, PhD, Geoffrey Matthews, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Olga Dashevsky, PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Tinghu Zhang, PhD, Megan Bariteau, Jeffrey Sorrell, BA, Nicholas P Kwiatkowski, PhD, Nathanael Gray, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 3343.

https://doi.org/10.1182/blood.V130.Suppl_1.3343.3343

Published: 2017

Journal Articles

In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment

Ryosuke Shirasaki, MD, Csikos Tamas, PhD, Geoffrey Matthews, PhD, Ricardo De Matos Simoes, PhD, Subhashis Sarkar, PhD, Olga Dashevsky, PhD, Hu Yiguo, PhD, Jeffrey Sorrell, BA, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Megan Bariteau, Brian Glassner, PhD, Aedin Culhane, PhD, Richard WJ Groen, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 4414.

https://doi.org/10.1182/blood.V130.Suppl_1.4414.4414

Published: 2017

NARROW

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors — Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications

In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Targeting Mutant KRAS with Novel Mutant-Specific Pharmacological Inhibitors: Activity Against Myeloma and Other Lymphoid Malignant Cells and Molecular Mechanisms of Resistance

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Systematic Characterization of the "Resistome" of Tumor Cells Against Panels of Small Molecule Inhibitors — Application in the Context of Inhibitors of Transcriptional Cyclin-Dependent Kinases (tCDKs) and Implications for Future "Individualized" Clinical Applications

In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only